tiprankstipranks
Trending News
More News >

Imunon to present translational data in supporting Phase 2 OVATION Study

IMUNON (IMNN) announced that an abstract highlighting IMNN-001 data based on an immune biomarker analysis from the Phase 2 OVATION 2 Study in women with newly diagnosed advanced ovarian cancer was accepted for poster presentation at the European Society for Medical Oncology, ESMO, Gynaecological Cancers Congress 2025, being held June 19-21, 2025 in Vienna, Austria. The abstract, titled “Immune biomarker analysis of the OVATION-2 trial, a randomized Phase I/II study of IL-12 gene therapy IMNN-001 in combination with Neo/Adjuvant Chemotherapy in newly-diagnosed advanced Epithelial Ovarian Cancer,” will be presented by Premal H. Thaker, M.D., Interim Chief of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, Director of Gynecologic Oncology Clinical Research at Washington University School of Medicine, OVATION 2 Study Chair and Study Chair of the Phase 3 OVATION 3 trial.

Don’t Miss TipRanks’ Half Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1